Kenneth M. Kennedy

Associate

Research Triangle Park
+1.919.314.5630

Kenneth.Kennedy@klgates.com

OVERVIEW

Kenneth Kennedy is an associate in the firm's Research Triangle Park office, where he is a member of the health care & FDA practice group. Kenneth's practice focuses on advising clients on a variety of FDA and health care regulatory matters, including drug, device and cosmetic labeling, advertising and manufacturing, research and clinical trial related issues, state and federal health care fraud and abuse, and state, federal and international data privacy and security. He also regularly assists clients with operational matters including the negotiation of supply chain, manufacturing, research and data transfer contracts.

PROFESSIONAL BACKGROUND

Prior to joining the firm, Kenneth was a summer associate in the firm's Research Triangle Park in 2016.

EDUCATION

- J.D., University of California at Los Angeles (UCLA) School of Law, 2017
- B.M., Appalachian State University, 2014

ADMISSIONS

- Bar of North Carolina

THOUGHT LEADERSHIP *POWERED BY HUB*

- 12 November 2020, COVID-19: FDA Warning Letters Address Fraudulent Products and Failures to Meet EUA Requirements (*Podcast*)
- 29 October 2020, ONC Interim Final Rule Delays Information Blocking Rule Initial Compliance Deadline (*Alerts/Updates*)

- 1 October 2020, Blocking and Tackling: What Every Health Care Provider's Legal, IT, and Compliance Teams Need to Know About Information Blocking to Make It Through the First Compliance Deadline's Goal Posts (*Alerts/Updates*)
- 27 August 2020, K&L Gates Triage: Q&A: What Sponsors and Investigators Need to Know about FDA's ClinicalTrials.gov Reporting Requirements (*Podcast*)
- 16 April 2020, COVID-19: UPDATED HHS Delivers Initial $30 Billion of CARES Act Provider Relief Funding Directly to Medicare Providers and Suppliers and Quickly Updates Terms and Conditions (*Alerts/Updates*)
- 16 April 2020, COVID-19: UPDATED HHS Delivers Initial $30 Billion of CARES Act Provider Relief Funding Directly to Medicare (*Alerts/Updates*)
- 15 April 2020, COVID-19: Regulatory Guidance and Flexibilities for the Clinical Research Community (*Alerts/Updates*)
- 7 April 2020, COVID-19: CARES Act Overview: Relevant Health Care Provisions (*Alerts/Updates*)
- 26 March 2020, COVID-19: K&L Gates Triage: FDA Facilitates Diagnostic Testing and Heightens Public Safety Efforts Amid Outbreak (*Podcast*)
- 24 March 2020, COVID-19: FDA Publishes Enforcement Policies – Ventilator/Respiratory & Remote Patient Monitoring Devices (*Alerts/Updates*)
- 20 February 2019, North Carolina Attorney General Proposes Stringent Data Breach Legislation (*Alerts/Updates*)
- 9 November 2018, CMS Issues Final Medicare PFS Rule for CY 2019 (*Alerts/Updates*)
- 16 October 2018, FDA Releases Guidance on How Recent Changes to the Common Rule May Affect FDA-Regulated Clinical Trials (*Alerts/Updates*)
- 6 August 2018, CMS Issues Proposed Medicare PFS Rule for CY 2019 (*Alerts/Updates*)
- 17 April 2018, K&L Gates Triage: Ride Sharing and Health Care Regulatory Considerations (*Podcast*)
- 20 March 2018, Increased Scrutiny of Patient Assistance Programs: Enforcement Overview and Considerations (*Alerts/Updates*)

AREAS OF FOCUS

- Health Care and FDA
- Food, Drugs, Medical Devices, and Cosmetics (FDA)